{"id":47999,"date":"2022-09-06T14:01:54","date_gmt":"2022-09-06T12:01:54","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/triumvira-immunologics-to-present-interim-clinical-data-from-ongoing-phase-1-2-trial-with-t-cell-therapy-tac01-her2-at-european-society-for-medical-oncology-2022-congress\/"},"modified":"2022-09-06T14:01:54","modified_gmt":"2022-09-06T12:01:54","slug":"triumvira-immunologics-to-present-interim-clinical-data-from-ongoing-phase-1-2-trial-with-t-cell-therapy-tac01-her2-at-european-society-for-medical-oncology-2022-congress","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/triumvira-immunologics-to-present-interim-clinical-data-from-ongoing-phase-1-2-trial-with-t-cell-therapy-tac01-her2-at-european-society-for-medical-oncology-2022-congress\/","title":{"rendered":"Triumvira Immunologics to Present Interim Clinical Data from Ongoing Phase 1\/2 Trial with T Cell Therapy TAC01-HER2 at European Society for Medical Oncology 2022 Congress"},"content":{"rendered":"
\n

AUSTIN, Texas & HAMILTON, Ontario–(BUSINESS WIRE)–Triumvira Immunologics<\/a> (\u201cTriumvira\u201d), a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors, <\/b>today announced that it will present interim clinical data from its ongoing TACTIC-2 clinical trial (NCT04727151<\/a>) for TAC01-HER2 in a poster presentation at the upcoming European Society for Medical Oncology (ESMO) Congress, being held Sept. 9-13, 2022 in Paris, France. TAC01-HER2 is a novel cell therapy that consists of genetically engineered autologous T cells expressing T-cell Antigen Coupler (TAC) that recognizes human epidermal growth factor receptor 2 (HER2).\n<\/p>\n

<\/a><\/p>\n

\nDetails of presentation:<\/b>\n<\/p>\n

\nTitle:<\/b> A Phase I\/II Trial Investigating Safety and Efficacy of Autologous TAC T Cells Targeting HER2 in Relapsed or Refractory Solid Tumors
\n
Presenter: <\/b>Benjamin L. Schlechter, M.D., GI-Medical Oncology at Dana-Farber Cancer Institute
\n
Abstract #: <\/b>778TiP
\n
Date:<\/b> Monday, Sept. 12, 2022
\n
Time:<\/b> 11:00 a.m. – 12:00 p.m. CEST
\n
Location:<\/b> Paris Expo Porte de Versailles, Hall 4\n<\/p>\n

\nAbstracts will be published online on the ESMO website<\/a> at 12:05 a.m. CEST on Sept. 5, 2022 (6:05 p.m. EDT on Sept. 4, 2022).\n<\/p>\n

\nPosters will be available to registered delegates on the ESMO Congress platform beginning Saturday, Sept. 10 at 9:00 a.m. CEST (3:00 a.m. EDT) and will remain available for the duration of the congress. A copy of the presentation will also be available under the Presentations & Publications<\/a> tab of the News & Resources section of the Company\u2019s website at the same time at https:\/\/triumvira.com\/<\/a>.\n<\/p>\n

\nAbout Triumvira Immunologics<\/b>\n<\/p>\n

\nTriumvira Immunologics, Inc. (\u201cTriumvira\u201d) is a clinical-stage company developing unique, non-gene edited, first-in-class targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors. The company\u2019s proprietary T cell Antigen Coupler (TAC) technology is a robust and versatile platform that activates natural T cell functions differently from cell therapies such as CAR-T and engineered T cell receptor (TCR) therapies. Triumvira is headquartered in Austin, Texas with research facilities in Hamilton, Ontario.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestor Relations:<\/b>
Stephanie Carrington
\n
ICR Westwicke
\n
Stephanie.Carrington@westwicke.com<\/a>
646-277-1282<\/p>\n

Media Relations:<\/b>
Karen Chase
\n
ICR Westwicke
\n
Karen.Chase@westwicke.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

AUSTIN, Texas & HAMILTON, Ontario–(BUSINESS WIRE)–Triumvira Immunologics (\u201cTriumvira\u201d), a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors, today announced that it will present interim clinical data from its ongoing TACTIC-2 clinical trial (NCT04727151) for TAC01-HER2 in a poster … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":["entry","post","publish","author-business","post-47999","format-standard","category-industry"],"yoast_head":"\nTriumvira Immunologics to Present Interim Clinical Data from Ongoing Phase 1\/2 Trial with T Cell Therapy TAC01-HER2 at European Society for Medical Oncology 2022 Congress - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/triumvira-immunologics-to-present-interim-clinical-data-from-ongoing-phase-1-2-trial-with-t-cell-therapy-tac01-her2-at-european-society-for-medical-oncology-2022-congress\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Triumvira Immunologics to Present Interim Clinical Data from Ongoing Phase 1\/2 Trial with T Cell Therapy TAC01-HER2 at European Society for Medical Oncology 2022 Congress - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"AUSTIN, Texas & HAMILTON, Ontario–(BUSINESS WIRE)–Triumvira Immunologics (\u201cTriumvira\u201d), a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors, today announced that it will present interim clinical data from its ongoing TACTIC-2 clinical trial (NCT04727151) for TAC01-HER2 in a poster ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/triumvira-immunologics-to-present-interim-clinical-data-from-ongoing-phase-1-2-trial-with-t-cell-therapy-tac01-her2-at-european-society-for-medical-oncology-2022-congress\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-06T12:01:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220902005352\/en\/1560900\/21\/Triumvira_Logo_2021.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/triumvira-immunologics-to-present-interim-clinical-data-from-ongoing-phase-1-2-trial-with-t-cell-therapy-tac01-her2-at-european-society-for-medical-oncology-2022-congress\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/triumvira-immunologics-to-present-interim-clinical-data-from-ongoing-phase-1-2-trial-with-t-cell-therapy-tac01-her2-at-european-society-for-medical-oncology-2022-congress\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Triumvira Immunologics to Present Interim Clinical Data from Ongoing Phase 1\\\/2 Trial with T Cell Therapy TAC01-HER2 at European Society for Medical Oncology 2022 Congress\",\"datePublished\":\"2022-09-06T12:01:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/triumvira-immunologics-to-present-interim-clinical-data-from-ongoing-phase-1-2-trial-with-t-cell-therapy-tac01-her2-at-european-society-for-medical-oncology-2022-congress\\\/\"},\"wordCount\":379,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/triumvira-immunologics-to-present-interim-clinical-data-from-ongoing-phase-1-2-trial-with-t-cell-therapy-tac01-her2-at-european-society-for-medical-oncology-2022-congress\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220902005352\\\/en\\\/1560900\\\/21\\\/Triumvira_Logo_2021.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/triumvira-immunologics-to-present-interim-clinical-data-from-ongoing-phase-1-2-trial-with-t-cell-therapy-tac01-her2-at-european-society-for-medical-oncology-2022-congress\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/triumvira-immunologics-to-present-interim-clinical-data-from-ongoing-phase-1-2-trial-with-t-cell-therapy-tac01-her2-at-european-society-for-medical-oncology-2022-congress\\\/\",\"name\":\"Triumvira Immunologics to Present Interim Clinical Data from Ongoing Phase 1\\\/2 Trial with T Cell Therapy TAC01-HER2 at European Society for Medical Oncology 2022 Congress - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/triumvira-immunologics-to-present-interim-clinical-data-from-ongoing-phase-1-2-trial-with-t-cell-therapy-tac01-her2-at-european-society-for-medical-oncology-2022-congress\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/triumvira-immunologics-to-present-interim-clinical-data-from-ongoing-phase-1-2-trial-with-t-cell-therapy-tac01-her2-at-european-society-for-medical-oncology-2022-congress\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220902005352\\\/en\\\/1560900\\\/21\\\/Triumvira_Logo_2021.jpg\",\"datePublished\":\"2022-09-06T12:01:54+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/triumvira-immunologics-to-present-interim-clinical-data-from-ongoing-phase-1-2-trial-with-t-cell-therapy-tac01-her2-at-european-society-for-medical-oncology-2022-congress\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/triumvira-immunologics-to-present-interim-clinical-data-from-ongoing-phase-1-2-trial-with-t-cell-therapy-tac01-her2-at-european-society-for-medical-oncology-2022-congress\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/triumvira-immunologics-to-present-interim-clinical-data-from-ongoing-phase-1-2-trial-with-t-cell-therapy-tac01-her2-at-european-society-for-medical-oncology-2022-congress\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220902005352\\\/en\\\/1560900\\\/21\\\/Triumvira_Logo_2021.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220902005352\\\/en\\\/1560900\\\/21\\\/Triumvira_Logo_2021.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/triumvira-immunologics-to-present-interim-clinical-data-from-ongoing-phase-1-2-trial-with-t-cell-therapy-tac01-her2-at-european-society-for-medical-oncology-2022-congress\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Triumvira Immunologics to Present Interim Clinical Data from Ongoing Phase 1\\\/2 Trial with T Cell Therapy TAC01-HER2 at European Society for Medical Oncology 2022 Congress\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Triumvira Immunologics to Present Interim Clinical Data from Ongoing Phase 1\/2 Trial with T Cell Therapy TAC01-HER2 at European Society for Medical Oncology 2022 Congress - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/triumvira-immunologics-to-present-interim-clinical-data-from-ongoing-phase-1-2-trial-with-t-cell-therapy-tac01-her2-at-european-society-for-medical-oncology-2022-congress\/","og_locale":"en_US","og_type":"article","og_title":"Triumvira Immunologics to Present Interim Clinical Data from Ongoing Phase 1\/2 Trial with T Cell Therapy TAC01-HER2 at European Society for Medical Oncology 2022 Congress - Pharma Trend","og_description":"AUSTIN, Texas & HAMILTON, Ontario–(BUSINESS WIRE)–Triumvira Immunologics (\u201cTriumvira\u201d), a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors, today announced that it will present interim clinical data from its ongoing TACTIC-2 clinical trial (NCT04727151) for TAC01-HER2 in a poster ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/triumvira-immunologics-to-present-interim-clinical-data-from-ongoing-phase-1-2-trial-with-t-cell-therapy-tac01-her2-at-european-society-for-medical-oncology-2022-congress\/","og_site_name":"Pharma Trend","article_published_time":"2022-09-06T12:01:54+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220902005352\/en\/1560900\/21\/Triumvira_Logo_2021.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/triumvira-immunologics-to-present-interim-clinical-data-from-ongoing-phase-1-2-trial-with-t-cell-therapy-tac01-her2-at-european-society-for-medical-oncology-2022-congress\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/triumvira-immunologics-to-present-interim-clinical-data-from-ongoing-phase-1-2-trial-with-t-cell-therapy-tac01-her2-at-european-society-for-medical-oncology-2022-congress\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Triumvira Immunologics to Present Interim Clinical Data from Ongoing Phase 1\/2 Trial with T Cell Therapy TAC01-HER2 at European Society for Medical Oncology 2022 Congress","datePublished":"2022-09-06T12:01:54+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/triumvira-immunologics-to-present-interim-clinical-data-from-ongoing-phase-1-2-trial-with-t-cell-therapy-tac01-her2-at-european-society-for-medical-oncology-2022-congress\/"},"wordCount":379,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/triumvira-immunologics-to-present-interim-clinical-data-from-ongoing-phase-1-2-trial-with-t-cell-therapy-tac01-her2-at-european-society-for-medical-oncology-2022-congress\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220902005352\/en\/1560900\/21\/Triumvira_Logo_2021.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/triumvira-immunologics-to-present-interim-clinical-data-from-ongoing-phase-1-2-trial-with-t-cell-therapy-tac01-her2-at-european-society-for-medical-oncology-2022-congress\/","url":"https:\/\/pharma-trend.com\/en\/triumvira-immunologics-to-present-interim-clinical-data-from-ongoing-phase-1-2-trial-with-t-cell-therapy-tac01-her2-at-european-society-for-medical-oncology-2022-congress\/","name":"Triumvira Immunologics to Present Interim Clinical Data from Ongoing Phase 1\/2 Trial with T Cell Therapy TAC01-HER2 at European Society for Medical Oncology 2022 Congress - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/triumvira-immunologics-to-present-interim-clinical-data-from-ongoing-phase-1-2-trial-with-t-cell-therapy-tac01-her2-at-european-society-for-medical-oncology-2022-congress\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/triumvira-immunologics-to-present-interim-clinical-data-from-ongoing-phase-1-2-trial-with-t-cell-therapy-tac01-her2-at-european-society-for-medical-oncology-2022-congress\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220902005352\/en\/1560900\/21\/Triumvira_Logo_2021.jpg","datePublished":"2022-09-06T12:01:54+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/triumvira-immunologics-to-present-interim-clinical-data-from-ongoing-phase-1-2-trial-with-t-cell-therapy-tac01-her2-at-european-society-for-medical-oncology-2022-congress\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/triumvira-immunologics-to-present-interim-clinical-data-from-ongoing-phase-1-2-trial-with-t-cell-therapy-tac01-her2-at-european-society-for-medical-oncology-2022-congress\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/triumvira-immunologics-to-present-interim-clinical-data-from-ongoing-phase-1-2-trial-with-t-cell-therapy-tac01-her2-at-european-society-for-medical-oncology-2022-congress\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220902005352\/en\/1560900\/21\/Triumvira_Logo_2021.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220902005352\/en\/1560900\/21\/Triumvira_Logo_2021.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/triumvira-immunologics-to-present-interim-clinical-data-from-ongoing-phase-1-2-trial-with-t-cell-therapy-tac01-her2-at-european-society-for-medical-oncology-2022-congress\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Triumvira Immunologics to Present Interim Clinical Data from Ongoing Phase 1\/2 Trial with T Cell Therapy TAC01-HER2 at European Society for Medical Oncology 2022 Congress"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47999","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=47999"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47999\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=47999"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=47999"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=47999"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}